Wechselwirkungen · Pravafenix
Pravafenix 40 mg/160 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-123823 · Präparat HOS-095735
Medicinal products metabolised by cytochrome P450 Pravastatin is not metabolised to a clinically significant extent by the cytochrome P450 system. This is why medicinal products that are metabolised by, or are inhibitors of, the cytochrome P450 system can be added to a stable regimen of pravastatin without causing significant changes in the plasma levels of pravastatin, as have been seen with other statins. The absence of a significant pharmacokinetic interaction with pravastatin has been specifically demonstrated for several medicinal products, particularly those that are substrates/inhibitors of CYP3A4 e.g. diltiazem, verapamil, itraconazole, ketoconazole, protease inhibitors, grapefruit juice and CYP2C9 inhibitors (e.g. fluconazole).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) protease (HOS-085623) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) itraconazole (HOS-084516) fluconazole (HOS-087945) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-17T01:00:00Z · SHA-256 555d912c3c1635440482163c25a3d73a1dd04513baaad39957f8d1035f451ae2 · Passage 131dfcdba8ebf74066693fef558685b50d43493c83c3586840302b797c844894 · Zeichen 1015–1761 im Abschnitt